Enlivex Ltd. Ordinary Shares
Enlivex Ltd. Ordinary Shares price
About Enlivex Ltd. Ordinary Shares
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
- Stock ticker
- ENLV
- Company
- Enlivex Therapeutics Ltd.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 151
- Launch date
- Jul 31, 2014
- Listed exchange
- NASDAQ
Financials
Summary: ENLV
Dividends
Enlivex Ltd. Ordinary Shares conversion tables
 |  |
|---|---|
| 0.5 ENLV | 0.13455 USD |
| 1 ENLV | 0.2691 USD |
| 5 ENLV | 1.345 USD |
| 10 ENLV | 2.691 USD |
| |
|---|---|
| 0.5 USD | 1.858 ENLV |
| 1 USD | 3.716 ENLV |
| 5 USD | 18.58 ENLV |
| 10 USD | 37.16 ENLV |
More to explore
FAQ
ENLV is trading at $0.27, -12.20% over the last 24 hours. Track live moves on the price chart at the top of this page.
The ENLV stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. ENLV is currently trading at $0.27, -12.20% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on ENLV price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. ENLV's P/E ratio is currently 0.00 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from ENLV; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against ENLV's historical range and other companies in the Healthcare sector.
Enlivex Therapeutics Ltd.'s market cap is currently 5.66M USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.